Kabra Drugs Limited announced major corporate developments following its board meeting on March 07, 2026, including approval for a name change to Aanjaay Industries Limited and a strategic expansion into Indonesia's defence sector through a joint venture partnership.

Name Change Approval Received

The company received formal approval from the Ministry of Corporate Affairs on March 06, 2026, for changing its name from Kabra Drugs Limited to Aanjaay Industries Limited. The approval letter, issued by the Registrar of Companies at CRC Manesar, confirms there is no objection to the proposed name change.

The approval is subject to compliance with Section 4(2), 4(3) and other applicable provisions of the Companies Act, 2013. The name reservation remains valid for 60 days from the approval date and is liable to be withdrawn if found unsuitable before final approval.

Strategic Defence Partnership with Indonesia

The board approved a strategic expansion of business operations in Indonesia through a bilateral Strategic Comprehensive Joint Venture Agreement with PT. Bhinneka Dwi Persada Indonesia. This partnership focuses on defence technology development, engineering, and manufacturing of defence systems in India, along with participation in defence procurement programs and export of jointly developed defence systems.

Joint Venture Agreement Details

According to the regulatory disclosure, the collaboration aims to leverage the expertise and capabilities of both parties for development, manufacturing, procurement, and supply of strategic defence equipment and related technologies. Currently, Kabra Drugs Limited does not hold any shareholding in PT. Bhinneka Dwi Persada, though the parties may explore incorporating a joint venture entity subject to mutually agreed terms.

The agreement establishes strategic cooperation in the defence sector without providing PT. Bhinneka Dwi Persada any special rights such as director appointment rights, share subscription preferences, or restrictions on capital structure changes in Kabra Drugs Limited. The Indonesian partner is not related to the promoter, promoter group, or group companies of Kabra Drugs Limited, and the transaction does not fall within the ambit of related party transactions.

Corporate Governance and Compliance

The board meeting was conducted on March 07, 2026, from 05:00 p.m. to 06:30 p.m. IST, with Managing Director Nanjappan Aravind (DIN: 01895602) signing the regulatory disclosure. The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full compliance with listing requirements.

This strategic expansion represents a significant shift for the company as it ventures into the defence technology sector while maintaining its commitment to supporting government initiatives and international partnerships. The name change to Aanjaay Industries Limited reflects the company's evolving business focus and strategic direction.

Kabra drugs Limited has officially notified the BSE about an upcoming Board of Directors meeting scheduled for February 13, 2026. The pharmaceutical company will convene this important meeting to review and approve its quarterly financial performance for the third quarter of fiscal year 2026.

Board Meeting Details

The meeting is set to take place on Friday, February 13, 2026, at 5:00 PM at the company's Corporate Office located at No. 3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai – 600033. The primary agenda focuses on the consideration and approval of unaudited financial results for the quarter ended December 31, 2025.

Regulatory Compliance

The board meeting has been scheduled in accordance with Regulation 33 of SEBI (Listed Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to submit their quarterly financial results within specified timeframes and follow prescribed disclosure procedures.

The meeting agenda also includes provisions for considering any other matters that may arise with the permission of the Chairman during the proceedings.

Trading Window Restrictions

In compliance with insider trading regulations, Kabra Drugs Limited has implemented a trading window closure for all relevant parties. The restriction affects promoters, directors, designated employees, and concerned connected persons, preventing them from dealing in the company's shares until 48 hours after the announcement of the financial results.

This precautionary measure ensures adherence to SEBI's insider trading prevention guidelines and maintains market integrity during the period leading up to and immediately following the results announcement.

Company Information

The notification was signed by Nanjappan Aravind, Managing Director (DIN: 01895602), and submitted to the BSE on February 6, 2026. Kabra Drugs Limited, incorporated under CIN L02423MP1989PLC005438, maintains its registered office at 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh.